SUMMARY Hyaluronic acid concentrations were measured by a laser nephelometric assay in serum samples from 50 patients with advanced disseminated neoplasm and 50 healthy controls matched for age and sex. The identity of hyaluronic acid was confirmed by a combination of electrophoretic and enzymatic techniques. The mean serum hyaluronic acid concentration for the control group was 1 09 mg/I, with a range of 0-4 mg/l. The mean concentration for patients with neoplastic disease was 10 38 mg/l, with a range of 0-100 mg/l. Sixty two per cent of the patients with disseminated neoplasm had serum hyaluronic acid concentrations above the control range. There was no correlation between the increased concentration of hyaluronic acid and tumour type, serum bilirubin, serum alkaline phosphatase, or serum urea concentrations. There was a higher incidence of hypercalcaemia in patients with increased hyaluronic acid concentrations, but the correlation between hyaluronic acid and calcium concentrations was not significant. In view of the possible role of hyaluronic acid in cellular differentiation and morphogenesis the finding of increased hyaluronic acid concentrations in patients with advanced neoplastic disease may be of fundamental importance in cancer biology.
Hyaluronic acid is a high molecular weight glycosaminoglycan composed of alternate glucosamine and glucuronic acid units. It has a key structural role in connective tissue ground substance' and is also found in unusually high concentrations in fetal tissues.2 Since 1957 there have been sporadic reports of hyaluronic acid production by certain tumours. 35 Hyaluronic acid is present in the urine of neonates but is not normally found in the urine of adults.6 In 1978 we reported the presence of hyaluronic acid in the urine of about 30% of patients with disseminated neoplasm. 7 Having developed a laser nephelometric assay for serum glycosaminoglycans we subsequently found that hyaluronic acid may be detected in low concentration in the serum of some healthy individuals. 8 We now report the presence of a striking increase in serum hyaluronic acid concentration in some patients with disseminated neoplasm.
Patients and methods
Fifty patients were studied, all of whom had well documented evidence of advanced neoplastic disease, including hepatic or skeletal metastases, or both. Samples of serum from venous blood were paired Accepted and group 3 consisted of patients whose serum hyaluronic acid concentration was clearly normal-that is, <4mg/l (12 patients). In group 1 83% of patients had increased serum concentrations of alkaline phosphatase, 46% had increased calcium values, 46% had increased urea values, and 36% had increased bilirubin values (table). In group 2 the results were as follows: increased alkaline phosphatase 93%, increased calcium 29%, increased urea 50%, and increased bilirubin 36%. In group 3 the figures were increased alkaline phosphatase 83%, increased calcium 25%, increased urea 33%, and increased bilirubin 33%. There was no clear correlation between serum hyaluronic acid concentrations and tumour type.
Glycosaminoglycans isolated from serum samples with raised hyaluronic acid concentrations by laser nephelometry showed an alcian blue positive electrophoretic band of mobility identical with that of standard hyaluronic acid at pH 9-2 ( fig 2) and pH 5 0. This band was totally destroyed by incubation with streptomyces hyaluronidase, which is highly specific for hyaluronic acid.10 This band could not be clearly identified in control samples or in samples from patients with neoplastic disease with normal serum hyaluronic acid concentrations.
Discussion
The finding of increased, in some cases greatly increased, serum concentrations of hyaluronic acid in more than half of the patients with disseminated neoplasm was unexpected. Clearly, the trace of hyaluronic acid found in the urine of some patients with disseminated neoplasm was but a shadow of the striking phenomenon reported here.'
The increased serum concentrations of hyaluronic acid in patients with neoplastic disease are unlikely to be due to hepatic or renal failure. There was no significant difference in serum bilirubin, alkaline phosphatase, or urea concentrations between the patients with increased serum hyaluronic acid concentrations and those with normal values. Slight increases in serum hyaluronic acid concentration have been reported in some patients with inflammatory disease, including rheumatoid arthritis, (up to 7-0 mg/1), but the mean value for this group (1 -07 mg/1) was not significantly different from that for the control group. " The incidence of hypercalcaemia in the patients with raised serum hyaluronic acid concentrations (46%) was higher than that in patients with normal serum hyaluronic acid values (25%), but this difference was not significant (p > 0 1). We have not encountered similar increases in serum hyaluronic acid concentration in cases of nonneoplastic hypercalcaemia. " 
is too small to allow firm conclusions to be made about the relation between hypercalcaemia and hyaluronic acidaemia in patients with neoplastic disease, but we suspect that both may be independent phenomena associated with terminal neoplastic disease. In our previous study the patients with hyaluronic acid in their urine were all dead at follow up after three months.7 In the present study we were able to assay serial samples in three patients and found rapidly rising serum hyaluronic acid concentrations up to the point of death (fig 3) .
Possible reasons for the increased serum concentrations of hyaluronic acid in patients with neoplastic disease include a release of hyaluronic acid from connective tissue ground substance by invading neoplastic cells, the inhibition of hyaluronic acid catabolism by the production of hyaluronidase inhibitors, and the production of hyaluronic acid by the tumour cells themselves or as a result of their interaction with normal cells.
Increased amounts of hyaluronic acid have been shown in some human tumour tissues-notably, neuroblastoma, breast tumours, adenocarcinoma of colon, mesothelioma, and Wilms' tumour.4 Increased serum hyaluronic acid concentrations have been reported in patients with neuroblastoma3 and in a case of Wilms' tumour.'2 In neither of these reports was the source of the hyaluronic acid clearly established, but in the case of Wilms' tumour the authors concluded that the production of hyaluronic acid was related to the tumour since concentrations decreased promptly and dramatically on treatment with vincristine and became normal after the tumour was removed. Further evidence that hyaluronic acid may be a product of'tumour cells comes from the finding that transformation of green monkey kidney cells with SV40 leads to an accumulation of excess hyaluronic'acid as compared with their counterpart normal cells.'3 On the other hand the work of Knudson etal suggests that the increased production of hyaluronic acid in patients with neoplastic disease may depend on an interaction between tumour cells and normal fibroblasts. '4 They found that coculture of human LX-1 lung carcinoma cells and normal human fibroblasts produced three times more hyaluronic acid than the sum of that produced by LX-1 and fibroblast cultures grown separately.
As hyaluronic'acid is found in particularly high concentrations in fetal tissues,2 increased serum hyaluronic acid concentrations in patients with neoplastic disease may be an oncofetal phenomenon. It would be a particularly interesting one as hyaluronic acid, as a non-protein is not (in our current concept of genetic information transfer) thought to be a direct gene product.
Of central importance in cellular differentiation, and hence in neoplasia, is the positional sense of a cell in relation to its fellows. Little is understood of mechanisms here, but the intricate patterns of the molecular scaffolding of the intercellular matrix may be important. In connective tissue ground substance hyaluronic acid exists as long intercellular chains of high molecular weight, into which are linked proteoglycans containing variable chains of chondroitin sulphates and keratan sulphates.'
In the field of pure speculation, the detailed molecular organisation of the intercellular hyaluronateproteoglycan complexes would seem morphologically suited to a role in intercellular information transfer. In even wilder speculation, might a cell surface defect in the neoplastic cell, which damages its ability to recognise the hyaluronic acid based intercellular scaffolding, lead to an increased production of hyaluronic acid analogous to the increased cellular synthesis of cholesterol in low density lipoprotein receptor defect?'5 Of course, there is no evidence for this at present, but there is already some evidence that hyaluronic acid has a role in intercellular communication,16 cell adhesion,'7 and morphogenesis. '8 Against this background the finding of considerably raised serum hyaluronic acid concentrations in patients with a wide range of neoplastic diseases may point to a phenomenon of fundamental importance in neoplasia.
